Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Amgen Inc. made a total of 55 dividend payments.
The sum of all dividends (adjusted for stock splits) is : $70.26
Date | Dividend | Adj Dividend |
---|---|---|
February 14, 25 | $2.38 | $2.38 |
November 18, 24 | $2.25 | $2.25 |
August 16, 24 | $2.25 | $2.25 |
May 16, 24 | $2.25 | $2.25 |
February 15, 24 | $2.25 | $2.25 |
November 16, 23 | $2.13 | $2.13 |
August 17, 23 | $2.13 | $2.13 |
May 17, 23 | $2.13 | $2.13 |
February 14, 23 | $2.13 | $2.13 |
November 16, 22 | $1.94 | $1.94 |
August 17, 22 | $1.94 | $1.94 |
May 16, 22 | $1.94 | $1.94 |
February 14, 22 | $1.94 | $1.94 |
November 15, 21 | $1.76 | $1.76 |
August 16, 21 | $1.76 | $1.76 |
May 14, 21 | $1.76 | $1.76 |
February 11, 21 | $1.76 | $1.76 |
November 13, 20 | $1.60 | $1.60 |
August 14, 20 | $1.60 | $1.60 |
May 15, 20 | $1.60 | $1.60 |
February 13, 20 | $1.60 | $1.60 |
November 14, 19 | $1.45 | $1.45 |
August 14, 19 | $1.45 | $1.45 |
May 16, 19 | $1.45 | $1.45 |
February 14, 19 | $1.45 | $1.45 |
November 15, 18 | $1.32 | $1.32 |
August 16, 18 | $1.32 | $1.32 |
May 16, 18 | $1.32 | $1.32 |
February 14, 18 | $1.32 | $1.32 |
November 16, 17 | $1.15 | $1.15 |
August 15, 17 | $1.15 | $1.15 |
May 15, 17 | $1.15 | $1.15 |
February 13, 17 | $1.15 | $1.15 |
November 14, 16 | $1.00 | $1.00 |
August 15, 16 | $1.00 | $1.00 |
May 13, 16 | $1.00 | $1.00 |
February 11, 16 | $1.00 | $1.00 |
November 12, 15 | $0.79 | $0.79 |
August 13, 15 | $0.79 | $0.79 |
May 12, 15 | $0.79 | $0.79 |
February 10, 15 | $0.79 | $0.79 |
November 10, 14 | $0.61 | $0.61 |
August 12, 14 | $0.61 | $0.61 |
May 13, 14 | $0.61 | $0.61 |
February 11, 14 | $0.61 | $0.61 |
November 12, 13 | $0.47 | $0.47 |
August 14, 13 | $0.47 | $0.47 |
May 14, 13 | $0.47 | $0.47 |
February 11, 13 | $0.47 | $0.47 |
November 13, 12 | $0.36 | $0.36 |
August 14, 12 | $0.36 | $0.36 |
May 14, 12 | $0.36 | $0.36 |
February 13, 12 | $0.36 | $0.36 |
November 15, 11 | $0.28 | $0.28 |
August 16, 11 | $0.28 | $0.28 |